New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
13:43 EDTJAZZJazz Pharma sees 2012 revenue to meet or exceed prior view of $575M-$585M
Consensus $592.91M. In presentation slides for the JPMorgan Global Healthcare Conference, Jazz Pharmaceuticals stated, "The company currently expects that, for the year ended December 31, 2012, reported total revenues will meet or exceed the guidance range provided on November 8, 2012. Guidance includes EUSA Pharma contribution from June 12, 2012 and Azur Pharma contribution from January 18, 2012, and excludes the Women’s Health business, which is now accounted for as discontinued operations."
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
08:15 EDTJAZZJazz Pharmaceuticals price target raised to $201 from $163 at Canaccord
Subscribe for More Information
October 17, 2014
07:53 EDTJAZZJazz Pharmaceuticals shares 'signifincantly undervalued,' says FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use